Combining GLP-1 drugs with hormones may lower uterine cancer risk
Medical Xpress
February 14, 2026
AI-Generated Deep Dive Summary
Combining GLP-1 receptor agonist medications, such as Ozempic, with progestin hormone therapy may significantly reduce the risk of developing endometrial cancer. A retrospective study published in JAMA Network Open found that women using this combination treatment had a notably lower risk of endometrial cancer compared to those who only used progestin alone. This discovery could have important implications for managing hormonal therapies and preventing cancer in women.
GLP-1 receptor agonists, commonly prescribed for type 2 diabetes and obesity, work by mimicking the hormone glucagon-like peptide-1 to regulate blood sugar levels. Progestins, synthetic versions of the hormone progesterone, are often used in hormonal treatments, such as hormone replacement therapy or contraception. The study analyzed data from a large health care system, including over 50,000 women who used progestin alone and nearly 17,000 who combined it with GLP-1 drugs. Results showed that those on the combination therapy had a 62% lower risk of developing endometrial cancer.
This finding is particularly significant for women undergoing progestin-based therapies, as they are already at an increased risk of endometrial cancer. By adding GLP-1 medications to their treatment regimen, they may benefit from both blood sugar control and reduced cancer risk. While further research is needed to confirm these findings and explore the mechanisms behind this protective effect, the study highlights a
Verticals
healthmedical
Originally published on Medical Xpress on 2/14/2026